Hedge fund managers have largely avoided SMID pharma companies in the race for a COVID-19 vaccine, despite our proprietary basket of these stocks being up 1,110% through mid-August.
Is this a missed opportunity, or a measured show of restraint?
Our CEO Jon Caplis recently shared some insights on the topic withInstitutional Investor.
Check out the full article below to learn more about whose portfolio has, and hasn’t, benefited from the global race for a vaccine